{"id":1002750,"date":"2022-04-28T02:32:23","date_gmt":"2022-04-28T06:32:23","guid":{"rendered":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/uncategorized\/greenbrook-tms-inc-nasdaqgbnh-expected-to-announce-quarterly-sales-of-11-70-million-defense-world.php"},"modified":"2022-04-28T02:32:23","modified_gmt":"2022-04-28T06:32:23","slug":"greenbrook-tms-inc-nasdaqgbnh-expected-to-announce-quarterly-sales-of-11-70-million-defense-world","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/tms\/greenbrook-tms-inc-nasdaqgbnh-expected-to-announce-quarterly-sales-of-11-70-million-defense-world.php","title":{"rendered":"Greenbrook TMS Inc. (NASDAQ:GBNH) Expected to Announce Quarterly Sales of $11.70 Million &#8211; Defense World"},"content":{"rendered":"<p><p>Wall Street analysts expect that Greenbrook TMS Inc. (NASDAQ:GBNH  Get Rating) will report sales of $11.70 million for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Greenbrook TMSs earnings, with the lowest sales estimate coming in at $10.70 million and the highest estimate coming in at $12.70 million. Greenbrook TMS reported sales of $11.31 million during the same quarter last year, which indicates a positive year over year growth rate of 3.4%. The firm is scheduled to issue its next earnings results  on Monday, January 1st.<\/p>\n<p>According to Zacks, analysts expect that Greenbrook TMS will report full-year sales of $67.33 million for the current fiscal year, with estimates ranging from $57.30 million to $82.00 million. For the next fiscal year, analysts anticipate that the business will report sales of $83.60 million, with estimates ranging from $63.40 million to $115.00 million. Zacks Investment Researchs sales averages are an average based on a survey of research analysts that cover Greenbrook TMS.<\/p>\n<p>Greenbrook TMS (NASDAQ:GBNH  Get Rating) last released its quarterly earnings results on Wednesday, March 30th. The company reported ($0.34) EPS for the quarter, beating analysts consensus estimates of ($0.38) by $0.04. Greenbrook TMS had a negative net margin of 47.42% and a negative return on equity of 189.28%. During the same quarter last year, the company posted ($0.60) earnings per share. <\/p>\n<p>Several large investors have recently modified their holdings of GBNH. Masters Capital Management LLC raised its stake in  Greenbrook TMS by 55.6% in the fourth quarter. Masters Capital Management LLC now owns 700,000 shares of the companys stock worth $2,954,000 after buying an additional 250,000 shares in the last quarter.  Virtu Financial LLC bought a new position in  Greenbrook TMS in the fourth quarter worth about $288,000.  AdvisorShares Investments LLC raised its stake in  Greenbrook TMS by 365.5% in the fourth quarter. AdvisorShares Investments LLC now owns 64,214 shares of the companys stock worth $281,000 after buying an additional 50,418 shares in the last quarter.  Royce & Associates LP raised its stake in  Greenbrook TMS by 8.0% in the fourth quarter. Royce & Associates LP now owns 223,500 shares of the companys stock worth $977,000 after buying an additional 16,598 shares in the last quarter.  Finally, Rockefeller Capital Management L.P. bought a new position in  Greenbrook TMS in the third quarter worth about $109,000. 16.73% of the stock is owned by hedge funds and other institutional investors. <\/p>\n<p>GBNH opened at $2.72 on Friday. The company has a fifty day moving average price of $3.18 and a 200-day moving average price of $4.68. The firm has a market capitalization of $48.42 million and a P\/E ratio of -1.70. The company has a debt-to-equity ratio of 2.26, a current ratio of 1.34 and a quick ratio of 1.34. Greenbrook TMS has a one year low of $2.70 and a one year high of $13.89. <\/p>\n<p>About Greenbrook TMS (Get Rating)<\/p>\n<p>Greenbrook TMS Inc, together with its subsidiaries, controls and operates a network of outpatient mental health services centers in the United States. Its centers specialize in the provision of transcranial magnetic stimulation (TMS) therapy, an FDA-cleared non-invasive therapy for the treatment of major depressive disorder and other mental health disorders, as well as related psychiatric services.<\/p>\n<p>Featured Stories<\/p>\n<p>Get a free copy of the Zacks research report on Greenbrook TMS (GBNH)<\/p>\n<p>For more information about research offerings from Zacks Investment Research, visit Zacks.com<\/p>\n<p>Receive News & Ratings for Greenbrook TMS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenbrook TMS and related companies with MarketBeat.com's FREE daily email newsletter.<\/p>\n<p><!-- Auto Generated --><\/p>\n<p>Continue reading here:<\/p>\n<p><a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.defenseworld.net\/2022\/04\/22\/greenbrook-tms-inc-nasdaqgbnh-expected-to-announce-quarterly-sales-of-11-70-million.html\" title=\"Greenbrook TMS Inc. (NASDAQ:GBNH) Expected to Announce Quarterly Sales of $11.70 Million - Defense World\">Greenbrook TMS Inc. (NASDAQ:GBNH) Expected to Announce Quarterly Sales of $11.70 Million - Defense World<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> Wall Street analysts expect that Greenbrook TMS Inc. (NASDAQ:GBNH Get Rating) will report sales of $11.70 million for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Greenbrook TMSs earnings, with the lowest sales estimate coming in at $10.70 million and the highest estimate coming in at $12.70 million.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/tms\/greenbrook-tms-inc-nasdaqgbnh-expected-to-announce-quarterly-sales-of-11-70-million-defense-world.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[431603],"tags":[],"class_list":["post-1002750","post","type-post","status-publish","format-standard","hentry","category-tms"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1002750"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1002750"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1002750\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1002750"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1002750"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1002750"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}